Pfizer, Germany’s BioNTech release new data on Covid-19 vaccine
The companies also said their Phase II/III study, slated to enroll about 30,000 participants, had already dosed more than 11,000.
The companies also said their Phase II/III study, slated to enroll about 30,000 participants, had already dosed more than 11,000.
The companies said they had started a Phase II/III trial BNT162b2. The news comes the day after Moderna announced the launch of its Phase III study and days after Pfizer and BioNTech signed a nearly $2 billion vaccine supply deal with the federal government.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.